Resected pancreatic adenocarcinoma: An Asian institution's experience

BACKGROUND: Pancreatic adenocarcinoma (PDAC) is highly lethal. Surgery offers the only chance of cure, but 5‐year overall survival (OS) after surgical resection and adjuvant therapy remains dismal. Adjuvant trials were mostly conducted in the West enrolling fit patients. Applicability to a general p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Kennedy Yao Yi, Chow, Edwin Wei Xiang, Jiang, Bochao, Lim, Cindy, Goh, Brian Kim Poh, Lee, Ser Yee, Teo, Jin Yao, Tan, Damien Meng Yew, Cheow, Peng Chung, Ooi, London Lucien Peng Jin, Chow, Pierce Kah Hoe, Lee, Joycelyn Jie Xin, Kam, Juinn Huar, Koh, Ye Xin, Jeyaraj, Prema Raj, Tan, Ek Khoon, Choo, Su Pin, Chan, Chung Yip, Chung, Alexander Yaw Fui, Tai, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551988/
https://www.ncbi.nlm.nih.gov/pubmed/33939335
http://dx.doi.org/10.1002/cnr2.1393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551988/
https://www.ncbi.nlm.nih.gov/pubmed/33939335
http://dx.doi.org/10.1002/cnr2.1393

Ejemplares similares